> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# GSK Advances Velzatinib Trials As Japan Grants Its Experimental Cancer Drug Orphan Status
- URL: https://www.bullished.co/gsk-advances-velzatinib-trials-as-japan-grants-its-experimental-cancer-drug-orphan-status-a1999aaa/
- Published: 2026-11-19T12:32:41.000Z
- Updated: 2026-11-19T12:32:41.000Z
- Description: Enrolment in the trial after prior treatment is ahead of schedule, and GSK expects results in the second half of 2027.
- Author: Matteo Parrino
- Tags: SEC Filings, GSK, Industry: Healthcare

[GSK](https://www.bullished.co/tag/gsk/), a global biopharma company, received Japanese [orphan drug designation](https://www.sec.gov/Archives/edgar/data/1131399/000165495426009980/a7721d.htm?ref=bullished.co) Thursday for velzatinib, its experimental treatment for gastrointestinal stromal tumour. In its announcement furnished to the U.S. Securities and Exchange Commission, GSK said enrolment in a late-stage trial after prior treatment is ahead of schedule.

## A Drug Built Around Resistance

Gastrointestinal stromal tumour is a rare cancer that usually develops in the stomach or small intestine. Approximately 80,000 to 120,000 people worldwide receive a diagnosis each year, and KIT gene mutations drive 80% of cases.

About [90% of patients](https://www.sec.gov/Archives/edgar/data/1131399/000165495426009980/a7721d.htm?ref=bullished.co) develop new KIT mutations after initial treatment, typically followed by relapse and limited treatment choices. GSK said currently approved tyrosine kinase inhibitors — drugs that block certain proteins — do not cover every clinically relevant primary and secondary KIT mutation.

Velzatinib is designed to block KIT selectively as a standalone treatment. GSK said it targets all clinically relevant primary mutations and key secondary mutations, aiming to address resistance and difficulties tolerating treatment.

Japan's Ministry of Health Labour and Welfare based the designation on the ongoing early-stage StrateGIST 1 trial in advanced disease. GSK characterized the tumour activity and tolerability seen in that study as promising. Velzatinib already has orphan designations in the US and EU and FDA Fast Track status.

## Trials Across Treatment Stages

GSK is speeding development through late-stage studies in advanced or metastatic disease, both as an initial treatment and after prior therapy. The initial-treatment study compares velzatinib with imatinib; the study after imatinib treatment compares it with sunitinib.

A separate mid-stage Japanese trial, StrateGIST J, is enrolling patients whose cancer has progressed or who cannot tolerate available treatments. Japan's age-adjusted annual incidence is approximately 4 cases per 100,000 people, which GSK described as among the world's highest. Outcomes have improved over the past two decades, but five-year survival remains substantially lower once the cancer spreads.

GSK plans to present seven abstracts at the Connective Tissue Oncology Society's annual meeting in Seoul, South Korea, running November 18–21\. The presentations include clinical results organized by KIT mutation and treatment stage, laboratory research on mutation coverage, and biomarker work.

## Another Step In Cancer Medicines

GSK's cancer business also gained [US accelerated approval](https://www.businesswire.com/news/home/20261117891577/en/Nelkarmi-neladalkib-approved-in-the-US-for-previously-treated-advanced-ALK-positive-non-small-cell-lung-cancer?ref=bullished.co) Tuesday for Nelkarmi, for previously treated advanced ALK-positive non-small cell lung cancer.

The company's chief scientific officer, Tony Wood, said: "Nelkarmi is our [second new medicine](https://www.businesswire.com/news/home/20261117891577/en/Nelkarmi-neladalkib-approved-in-the-US-for-previously-treated-advanced-ALK-positive-non-small-cell-lung-cancer?ref=bullished.co) approved in lung cancer this year."

GSK develops cancer medicines across blood, lung, gastrointestinal, genitourinary and gynaecological cancers, using targeted small molecules, antibody-drug conjugates and immunotherapies. Its market value stood at $97.4 billion Thursday.

GSK expects results from the late-stage velzatinib trial after prior treatment in the second half of 2027.

### Sources

- [Form 6-K — VELZATINIB OBTAINS ODD IN JAPAN FOR GIST TREATMENT](https://www.sec.gov/Archives/edgar/data/1131399/000165495426009980/a7721d.htm?ref=bullished.co) — SEC EDGAR
- [IN BRIEF: GSK secures accelerated approval of Nelkarmi in US | Morningstar](https://www.morningstar.com/news/alliance-news/1794981327548629600/in-brief-gsk-secures-accelerated-approval-of-nelkarmi-in-us?ref=bullished.co) — morningstar.com
- [GSK plc Form 6-K filed November 17, 2026](https://www.sec.gov/Archives/edgar/data/1131399/000165495426009909/a5197d.htm?ref=bullished.co) — sec.gov
- [Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer](https://www.businesswire.com/news/home/20261117891577/en/Nelkarmi-neladalkib-approved-in-the-US-for-previously-treated-advanced-ALK-positive-non-small-cell-lung-cancer?ref=bullished.co) — businesswire.com

### More on GSK

- [GSK Gets EU Panel Backing To Extend Bexsero Protection With An Adolescent Booster](https://www.bullished.co/gsk-gets-eu-panel-backing-to-extend-bexsero-protection-with-an-adolescent-booster-8af67ffd/)
- [GSK Says 'No Read Across' From HIV Prevention Shot Analysis To Treatment Version](https://www.bullished.co/gsk-says-no-read-across-from-hiv-prevention-shot-analysis-to-treatment-version-2859e9a2/)
- [GSK CEO Vows Not To 'Park Crap On Page 41' Of A Press Release](https://www.bullished.co/gsk-ceo-vows-not-to-park-crap-on-page-41-of-a-press-release-c4119057/)

[All GSK (GSK) coverage →](https://www.bullished.co/tag/gsk/)